secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lexeo Therapeutics, Inc. (LXEO)
CIK:        0001907108
Form:       8-K
Filed at:   2025-03-24T23:59:59+00:00
Accession:  0000950170-25-043485
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lexeo Q4 net loss $25.9M; FDA aligns on LX2006 accelerated path; LX2020 shows protein expression increases
--------------------------------------------------------------------------------

- Net loss $25.9M ($0.78/sh) for Q4 2024 vs $14.2M; FY net loss $98.3M ($3.09/sh) vs $66.4M.
- Cash $128.5M expected to fund operations into 2027.
- FDA agrees to use frataxin expression increase from baseline as co-primary endpoint for LX2006 pivotal study.
- LX2020 cohort 1: PKP2 protein increased 71% and 115% from baseline; first participant saw 67% PVC reduction.
- LX2020 cohort 2 fully enrolled; interim clinical data expected H2 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1907108/000095017025043485/0000950170-25-043485-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1907108/000095017025043485/lxeo-20250324.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-043485

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer